Figure 8.

Potential agents for patients with high CMLS

(A) Discovery of pathways significantly activated in the high-CMLS group through the GSEA algorithm. (B) Pre-predicting the sensitivity of cisplatin to validate the feasibility of the computational algorithm. (C) The comprehensive computational pipeline for the screen of potential agents. (D and E) The correlation and differential analysis of drug sensitivity for potential drugs screened from the CTRP and PRISM datasets. (F and G) The unpaired and paired differential expression analyses for potential target gene of screened drugs in normal and tumor tissue. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.